Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05195385
Recruiting Not applicable

Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study

NCT05195385 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Not applicable
Started
2022-04-08
Last updated
2026-03-30

Condition(s) studied

Lung Cancer Screening

Investigational drug(s) / intervention(s)

Low-dose computed tomography of the chest

Low-dose computed tomography of the chest: Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules

Study summary

The purpose of this study is to determine whether reading of low-dose thoracic CT scans can be done by a single general radiologist who has been trained to lung cancer screening, and will evaluate the performance in comparison with double reading by experts.

The study will enroll women between 50 and 74 years old, at risk for lung cancer due to their smoking history.

Eligibility

Sex
FEMALE
Min age
50 Years
Max age
74 Years
Healthy volunteers
No
Inclusion Criteria: * Women aged from 50 to 74 years * who had smoked at least 20 pack years and quit less than 15 years ago * Had given their consent and accepted the need for a 2-year follow-up * Affiliated to the social security system Exclusion Criteria * Presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever) * Evolving cancer * History of lung cancer * A 2-year follow-up not possible * Chest CT scan performed within 2 years prior to inclusion

Primary outcome measure(s)

  • Performance of trained radiologists for lung cancer screening — 2 years
    Sensitivity, specificity, predictive values compared to double reading by experts

Trial sites (1)

FacilityCityRegionStatus
Hôtel-Dieu Paris France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting
VExUS in Ards Patients and Association with AKI Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting
Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation Starting soon
Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05195385 on ClinicalTrials.gov ↗ ← All trials in France